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Abstract 
 
Polypharmacy, defined as the concurrent use of four or more medications by a single 
patient, is ever-increasing. It enhances the risk of adverse drug reactions (ADRs) and can 
represent a huge burden to patients. Medication reviews are the proposed panacea for 
reducing such problematic polypharmacy. These reviews conducted on patients aged 65 
years or over can be aided by activation of the STOPP/START toolkit, an electronic tool that 
gives alerts, specific to a patient’s current medication regime, to recommend that GPs stop 
and/or start certain medications. Unique to this toolkit, the alerts are significantly associated 
with the Royal College of General Practitioners (RCGP) prescribing safety indicators – 
indicators designed to reduce ADRs – and, thus, the toolkit attempts to enhance patient 
safety. The aim of this study was to determine whether the STOPP/START toolkit improves 
medication reviews conducted on elderly polypharmacy patients. 
 
Forty patients aged 75 years or over, all of whom were registered with a North Kirklees 
commissioned GP practice, were currently prescribed ten or more medications, and had 
received a STOPP/START medication review, formed the study’s participant cohort. 
Recruited patients were asked a series of questions via a retrospective telephone interview 
to help determine the patient-perceived usefulness of, and satisfaction with, the medication 
review. Data regarding the number of alerts identical or similar to the RCGP prescribing 
safety indicators of defined ‘high’ (level 3) or ‘extreme’ (level 4) risk that were triggered and 
resolved during the North Kirklees commissioned STOPP/START medication reviews was 
also accessed and analysed. This helped to determine whether improved patient safety 
could be deemed an attribute of STOPP/START. 
 
It was found that 75% of patients believed their medication review was useful, regardless of 
whether any medications were stopped and/or started. If medications were stopped and/or 
started, patients felt greater involvement in and heightened satisfaction with the change(s) 
made if change(s) were based on STOPP/START recommendations (p<0.1). Furthermore, 
in North Kirklees, 388 STOPP/START alerts linked to level 3/4 RCGP indicators were 
resolved; these resolutions potentially prevented 78 hospital admissions. 
 
This study suggests that the stopping and/or starting of medications is not crucial in 
establishing overall patient satisfaction in medication reviews. Instead, it would seem that 
elderly patients merely desire the opportunity to discuss their medications with a healthcare 
professional. However, the STOPP/START toolkit can help to improve patient safety, and 
can better engage patients in decisions for medication change(s), heightening patient 
satisfaction with the change(s). This suggests that activation of the STOPP/START toolkit in 
polypharmacy medication reviews conducted on the elderly would be beneficial. 
 
Keywords: Polypharmacy; STOPP/START; medication review; adverse drug reactions; 
elderly; patient safety. 
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Introduction 
 
Purpose 
 
Multimorbidity, defined as the co-occurrence of two or more chronic medical conditions in an 
individual, is ever-increasing (Koné-Pefoyo et al., 2015), with estimates suggesting the 
applicability of this term to one in six UK patients (Salisbury, Johnson, Purdy, Valderas, & 
Montgomery, 2011). Most clinical prescribing guidelines are condition specific and so do not 
view multimorbid patients holistically. This results in complex medication regimes and a 
consequent increased likelihood of polypharmacy. 
 
In some patient cases, polypharmacy may be beneficial and will enhance the quality of life, 
termed ‘appropriate polypharmacy’. However, polypharmacy can be problematic, as it may 
present a huge burden to a patient, and/or the intended benefit may not be achieved. Such 
problems with polypharmacy most often arise when prescribing becomes incremental and 
more drugs are added to treat side effects of other drugs (Duerden, Avery, & Payne, 2013). 
These problems are then worsened by a prescriber’s reluctance to deprescribe medicines 
that present a risk outweighing the potential benefit (Reeve, Gnjidic, Long, & Hilmer, 2015). 
 
Inappropriate polypharmacy also enhances the likelihood of hospital admission (Davies & 
O’Mahony, 2015) owing to the increased potential for drug interactions and the occurrence 
of adverse effects (Pirmohamed et al., 2004). Hospital admission can cause a deterioration 
in a patient’s overall health and also places more stress on the NHS, as potentially avoidable 
hospital admissions demand resources. 
 
Owing to the potential risks of polypharmacy, it is important that GPs have annual 
appointments with polypharmacy patients specifically to review the medication prescribed. 
Such an appointment is termed a polypharmacy medication review (PMR). PMRs can be 
streamlined through the use of tools. One such tool, designed for a population group at high 
risk of polypharmacy – those aged 65 years or above – is the combined Screening Tool of 
Older Persons’ potentially inappropriate Prescriptions (STOPP) and the Screening Tool to 
Alert doctors to Right Treatment (START) (Hamilton, Gallagher, Ryan, Byrne, & O’Mahony, 
2011). This tool is being commissioned to supplement PMRs in some primary care settings 
in England. 
 
Aim 
 
The aim of this study was to determine whether the STOPP/START toolkit improves the 
medication reviews conducted on elderly polypharmacy patients. 
 
Objectives 
 
These were as follows: 
 To determine: 
o The extent of, and reasons for, patient satisfaction with STOPP/START-aided 
PMRs; 
o Whether STOPP/START-aided PMRs can enhance patient understanding of 
both the need for and how to take/use their medications; 
o The extent to which patients feel involved in decisions to stop and/or start 
medications in STOPP/START-aided PMRs; 
o Whether patient-perceived involvement affects patient satisfaction in 
decisions to stop and/or start medications in STOPP/START-aided PMRs; 
o The extent to which the STOPP/START toolkit can decrease risks of adverse 
drug reactions (ADRs). 
 To give a recommendation on whether the STOPP/START toolkit should be 
commissioned for use in PMRs. 
 
 
 
Literature review 
 
Polypharmacy 
 
Between 2001 and 2010, there was a 53.8% rise in the average number of items prescribed 
per person per year, with numbers continuing to increase. Subsequently, there is also a rise 
in polypharmacy (Health and Social Care Information Centre (HSCIC), 2012). A Scottish 
study provides evidence for an increase in polypharmacy in Great Britain, reporting that the 
proportion of 310,000 adult patients receiving between five and nine repeat medications 
increased from 9.7% to 16.3% between 1995 and 2010. Over the same time period, the 
proportion of the same cohort receiving ten to fourteen medications also increased, from 
1.5% to 4.7% (Guthrie, Makubate, Hernandez-Santiago, & Dreischulte, 2015). This increase 
in polypharmacy prevalence is considered to be due to an increase in diagnosed 
multimorbidity (Duerden et al., 2013). 
 
Polypharmacy and the elderly 
 
A patient with a diagnosis of two or more conditions is deemed to be multimorbid (Koné-
Pefoyo et al., 2015). Multimorbidity prevalence increases with age (Barnett, Obho, & Smith, 
2015). When treating conditions, clinicians are encouraged to follow clinical guidelines. 
These guidelines are, however, non-holistic; thus, in a multimorbid patient, one guideline has 
to be followed for each condition diagnosed. As multimorbid patients have multiple 
diagnoses, multiple guidelines are required, each offering multiple drug therapies, and this 
can quickly result in complex, multi-drug regimes. Owing to this link between multimorbidity, 
increasing age and polypharmacy, the elderly form the largest proportion of prescribed 
medication takers (Scholes, Faulding, & Mindell, 2014). 
 
Polypharmacy and poor adherence 
 
NHS England defines medication adherence as an instance in which a patient takes their 
medication in line with agreed prescriber recommendations. Deviation from this ideal – non-
adherence – can be either intentional, for example, deliberate failure to take medication 
owing to unwanted side effects or personal beliefs, or unintentional, as a result of 
forgetfulness, uncertainty of the need for a medication, or uncertainty about how and when 
to take it (NHS England, 2015). 
 
It is estimated that 50% of patients are non-adherent with at least one medication (NHS 
PrescQIPP, 2013). The Department of Health (DoH) suggests that the more medicines that 
are concurrently prescribed, the lower the manageability and the greater the patient 
uncertainty about the medication regime, which causes greater non-adherence, particularly 
in the elderly (DoH, 2001). This is also supported by findings documented in the report 
‘Dispensing Health in Later Life’ (Pharmacy Voice, 2015). 
 
Polypharmacy and adverse drug reactions 
 
Polypharmacy enhances the risk of ADRs (Davies & O’Mahony, 2015). Prybys, Melville, and 
Hanna (2002) found that the risk of ADRs increases from 13% for a patient taking two 
regular medications to 58% for a patient taking five regular medications, and to 82% for 
seven or more regular medications. ADRs enhance the risk of hospital admissions. 
Pirmohamed et al. (2004) reported on 18,820 admissions, and found that 1,225 (6.5%) of 
these admissions were ADR related. 
 
The Royal College of General Practitioners (RCGP) has recognised that certain prescribing 
events can enhance the risk of potentially fatal ADRs (Spencer, Bell, Avery, Gookey, & 
Campbell, 2014). Consequently, it has released 56 prescribing safety indicators (RCGP, 
2014), which should be followed by practitioners in primary care in an attempt to decrease 
ADR risk and consequently increase patient safety. It is of particular importance that these 
indicators are considered when reviewing polypharmacy patients, as such patients are most 
at risk of ‘unsafe’ prescribing. 
 
Managing polypharmacy 
 
It is important that in practice, problematic polypharmacy is identified and rectified. One 
proposed method to achieve this is the conducting of a medication review (Wallace et al., 
2015). According to the National Institute for Health and Care Excellence (NICE), a 
structured, patient-facing medication review of 20 minutes’ duration should be conducted at 
least once per annum on polypharmacy patients. The aim is for the review to better optimise 
a patient’s medication regime and to enhance patient understanding of the need for, and of 
how to use, their medicines (NICE, 2015). 
 
As the elderly are more likely to have polypharmacy regimes, a greater demand for effective 
medication review is required within this patient group. To better streamline the review 
process of patients aged 65 years or over, GPs are being encouraged to implement the 
STOPP/START tool. STOPP comprises 65 evidence-based indicators of potentially 
inappropriate medicines and START consists of 22 evidence-based indicators for prescribing 
in common long-term health conditions seen in the elderly (Hamilton et al., 2011). Most 
medicines that appear in the STOPP/START alerts are significantly associated with ADRs, 
as most alerts are linked with the RCGP prescribing indicators (RCGP, 2014). Reviewing 
and, where necessary, implementing alert guidance should, therefore, decrease the 
incidence of potentially avoidable ADR-related hospitalisation (Hamilton et al., 2011). 
 
Patient satisfaction with medication reviews 
 
The White Paper ‘Equity and Excellence: Liberating the NHS’ (DoH, 2010) formed the basis 
of the NHS Outcomes Framework. Domain 4 of this framework relates to the assurance that 
‘people have a positive experience of care’, and implies that patients should leave a 
medication review feeling satisfied (DoH, 2013). It is believed that the greater the level of 
patient satisfaction following a medication review, the more adherent that patient will be to 
their medication regime (The Health Foundation, 2012). One literature review identified 
‘patient-perceived discussion involvement’ and ‘shared decision-making’ to be the most 
pivotal factors in enhancing patient satisfaction (Suh & Lee, 2010). 
 
Shared decision-making recognises that both clinicians and patients have knowledge 
regarding medications. Clinicians possess clinical knowledge and are aware of evidence-
based prescribing guidelines, whereas patients possess more practical knowledge and will 
often have personal preferences for certain medications (Butterworth & Campbell, 2014). 
Shared decision-making deems clinical guidance and patient preference to be of equal 
importance (Foot et al., 2014), and, in line with recommendations made in the Five Year 
Forward View (5YFV), it attempts to give patients greater control of their own care (NHS 
England, 2014). In order for a medication review to be successful, shared decision-making 
should be practised (NICE, 2009). 
 
Design/methodology/approach 
 
Study design 
 
This study was retrospective in nature and involved two methods of data collection to 
determine whether the STOPP/START toolkit improves the medication reviews conducted 
on elderly polypharmacy patients. Firstly, information was retrieved from patients via a 
telephone interview. All interviews were conducted within a five-month time frame post-PMR, 
and all interviews followed a standardised framework. The framework comprised a brief, 
scripted introduction, followed by ten set questions. Eight of these questions were essential 
to all interviews conducted, and two were required only if the patient had at least one 
medication stopped and/or started during their medication review. 
 
Of the ten questions, nine were designed to elicit nominal data, and one Likert-style question 
was designed to elicit ordinal data. All ten questions were thus suitable for quantitative 
analysis. Qualitative data was also retrieved, as following three of the questions, participants 
were asked to give one reason for their answers. 
 
STOPP/START alerts are designed such that some are either identical or similar to RCGP 
prescribing safety indicators. Therefore, to achieve the objective of determining the extent to 
which the STOPP/START toolkit can decrease the risk of ADRs, the second aspect of the 
data collection involved downloading and analysing the number of alerts identical or similar 
to the RCGP prescribing safety indicators defined as ‘high’ (level 3) or ‘extreme’ (level 4) risk 
that were triggered and resolved during the PMRs in North Kirklees. 
 
Study population and subject definition 
 
North Kirklees Clinical Commissioning Group (NKCCG) commissioned GP practices in North 
Kirklees to perform a 20-minute STOPP/START-aided PMR on all patients aged 75 years or 
over, who were co-prescribed ten or more repeat medications. All reviews were conducted 
between September 2015 and January 2016. These patients formed the study’s participant 
cohort. 
 
Some patients within this category were, however, excluded from the study. The exclusion 
factors were: 
 
 Patients clinically diagnosed with dementia of any form, amnesia, schizophrenia 
and/or severe depression; 
 Patients known to have a poor understanding of English. 
 
Of the 28 NKCCG member practices, ten refused to conduct PMRs, six conducted two or 
fewer PMRs, six were dominated by patients who had a poor understanding of English and 
two were inconvenient to visit. Patients at these surgeries were thus not contacted to 
complete a telephone interview. All telephone interview data was, therefore, retrieved from 
patients meeting the selection criteria who were registered at the remaining four surgeries. 
 
However, the database containing information regarding the number of alerts identical or 
similar to the level 3/4 RCGP prescribing safety indicators that were triggered and resolved 
could not be manipulated to exclude certain patient groups. Therefore, unlike the data 
retrieved from the patient interviews, RCGP prescribing safety indicator data included all 
consenting patients who received an NKCCG-commissioned PMR at any of the 28 NKCCG 
member practices between September 2015 and January 2016. 
 
Subject recruitment 
 
Immediately after the PMR, in abidance with STOPP/START guidance set by the NKCCG 
Medicines Management Team, GPs were required to ask patients whether they would 
consent to completing a telephone interview regarding feedback on their review. This was 
done by most doctors, and if consent had been granted by the patient, the ‘provision of 
patient satisfaction questionnaire’ box found in a patient’s records was ticked. The status of 
this box was checked by the interviewer, and only patients with a ticked box were contacted. 
 
Problems arose, however, as some doctors admitted to forgetting to ask for consent. 
Patients reviewed by these doctors, therefore, appeared to have withheld consent, which 
limited the number of potential participants. In such cases, the doctors gave permission for 
patients to be contacted, at which time verbal patient consent was requested over the phone 
through use of a ‘consent script’. These patients were also given the option to receive more 
information before making a decision to consent. If requested, a patient information sheet 
and consent form were posted to the patient’s home address. 
 
Ethics 
 
To comply with the University’s Code of Practice for Research and the University’s Research 
and Ethics Integrity Policy, ethical approval had to be granted. This is because the study 
involved potentially vulnerable members of the general public. A protocol was, therefore, 
submitted to the Ethics Committee. This protocol was approved. 
 
Withdrawal or early termination 
 
All patients were made aware that they did not have to give consent, and that consent could 
be withdrawn at any time without any repercussions. 
 
Number of subjects 
 
Attempts were made to contact 85 patients; however, only 40 attempts were successful, and 
so 40 fully completed telephone interviews were retrieved. Of the 40 respondents, 20 did 
and 20 did not have at least one medication stopped and/or started during their PMR. This 
equal result (20:20) allowed a fair comparison of the two groups. 
 
Data collection 
 
Data was collected from the consenting polypharmacy patients. The outcomes measured 
were: 
 The extent to which patients felt satisfied with their medication review as a whole; 
 The level of understanding possessed by patients regarding their medications pre- 
and post-review; 
 The degree of patient-perceived involvement in decisions to stop and/or start 
medications; 
 The extent to which patients felt satisfied with medication additions and/or omissions, 
where the GP had deemed such changes necessary; 
 The extent to which the STOPP/START toolkit decreases ADR risk. 
 
Confidentiality of subject identity and data 
 
All patient-identifiable features were omitted from this study to ensure all participants 
remained anonymous. 
 
Data analysis 
 
Responses to each of the ten questions in the telephone interview were analysed. For the 
quantitative responses, Microsoft Excel was used to create a series of bar charts, and for the 
qualitative responses, a series of themes were identified. Despite the relatively small sample 
size, statistical analysis in the form of an independent samples t-test (a parametric 
procedure) and Spearman’s Rho correlation analysis (a non-parametric procedure) was also 
conducted on aspects of the data collected. This was to determine any differences in 
response, firstly between patients who did and patients who did not have any medications 
stopped and/or started during their review; and secondly, between patients who had a 
STOPP/START-initiated change and patients who had a GP-initiated change (i.e. a medicine 
added and/or omitted independent of a STOPP/START alert). This was achieved using the 
IBM SPSS Version 22 software. A significance level of 0.1 was used to reduce chances of a 
type II error, and thus incorrect acceptance of a false null hypothesis, as likelihood of type II 
error is heightened with small data sets such as the one in the study. 
 
STOPP/START-generated information regarding the triggering and resolution of RCGP 
prescribing safety indicator linked STOPP/START alerts was also quantitatively analysed. 
 
Findings 
 
Patient-perceived usefulness of PMRs 
 
Domain 4 of the NHS Outcomes Framework attempts to ensure that all patients have a 
positive care experience and leave the care setting satisfied (DoH, 2013). In terms of a PMR 
undertaken in primary care, patient-perceived usefulness is likely to correlate with patient 
satisfaction. When asked, 75% (30) of the patients interviewed felt their review was useful 
and, hence, were likely to have left satisfied, with only a handful stating that they found the 
review to be of no use (17.5%). There was no significant difference (p>0.1) in patient-
perceived usefulness between patients who had and patients who had not had at least one 
medication stopped and/or started during their PMR. This suggests that the main patient-
perceived purpose of a PMR is not to amend medicines, and so patient satisfaction cannot 
be solely attributed to activation of the STOPP/START toolkit. 
 
Three of the patients (7.5%) were undecided on perceived PMR usefulness. This may have 
been due to poor patient understanding of the purpose of a PMR, as patients cannot 
determine need fulfilment without first understanding the intended review need. If this is true, 
more information regarding the review and its purpose may be required by patients before a 
review is conducted, to ensure that maximum review potential is achieved. 
 
Patients were also asked to give one reason for their perception of PMR usefulness. 
One clear theme that presented from these qualitative answers was patient gratitude for 
specific time to discuss medicines, with 41.66% (15) of the 36 ‘significant’ patient responses 
stating this as their reason for perceiving the PMR to be useful. Results, therefore, support 
the recommendation that PMR duration should be 20 minutes, despite this being twice the 
length of an average primary care consultation (NICE, 2015). 
 
Patient understanding of their medications post-PMR 
 
One desired outcome of a PMR, as stated by NICE, is to increase patient understanding with 
regard to their medication, in the hope that increased understanding will decrease 
unintentional non-adherence (NICE, 2015). Results indicate that the PMRs achieved this 
outcome, as 80% (32) of patients reported a better understanding of both what their 
medicines were for and how to take/use their medicines post-review. 
 
The DoH identified poor patient understanding as a contributing factor in non-adherence, 
with the inference that the greater the extent of polypharmacy, the greater the patient 
confusion regarding the regime, and, hence, the poorer the adherence (DoH, 2001). The 
results, however, showed no significant difference (p>0.1) in enhanced patient 
understanding of both medication indication and administration between patients who had 
and patients who had not had at least one medication stopped and/or started during their 
PMR. Therefore, although it is true that with more medicines there is a greater potential for 
confusion, it seems that patient understanding can be improved without the need for drug 
elimination. Hence, the results suggest that PMRs can improve patient understanding 
without activation of the STOPP/START tool. 
 
Shared decision-making 
 
Patient-perceived inclusion in decisions to change medication regimes should enhance 
patient adherence, and this is a desirable outcome (Suh & Lee, 2010; The Health 
Foundation, 2012). Of the 20 patients who had at least one medication added and/or omitted 
during their PMR, only 50% (ten) reported feeling involved in the decision for this change. 
The remaining 50% (ten) stated that they were not involved in such decision-making. This 
suggests that clinicians need more training regarding shared decision-making to improve 
PMRs. 
 
Interestingly, further analysis of the results uncovered that patients perceived that 
involvement in decision-making was much more likely if changes were initiated by 
STOPP/START, as opposed to by GPs, independent of STOPP/START. This difference was 
deemed significant (p<0.1). 
 
The 20 patients who had at least one medication stopped and/or started during their review 
were also asked whether they were satisfied with the medication additions and/or omissions. 
Spearman’s Rho correlation analysis uncovered a significant positive correlation between 
patient-perceived involvement and patient-perceived satisfaction with regard to their 
medication changes (r=0.905, p<0.1). This correlation illustrates that patient-perceived 
involvement in decisions to add and/or omit medications enhances the likelihood of patient 
satisfaction in these changes. The results, therefore, suggest patient involvement to be 
essential in the achievement of patient satisfaction in medication reviews and, hence, as it 
enhances patient-perceived inclusion, they also support activation of the STOPP/START 
toolkit. 
 
Patient safety 
 
RCGP indicators recognise and attempt to lower the risks of ADRs (RCGP, 2014). Of the 
STOPP/START indicators used locally by NKCCG, 13 correspond with the level 3/4 RCGP 
indicators. Within the NKCCG-commissioned PMRs conducted between September 2015 
and January 2016, these 13 STOPP/START indicators were triggered 913 times. Triggers 
were resolved in 388 cases, giving an overall percentage resolution of 42.5%. 
 
It is estimated that one in five patients with medication regimes that correspond to RCGP 
indicators of levels 3 or 4 would require hospital admission over a 12-month period (RCGP, 
2014). In accordance with this estimation, the 388 STOPP/START indicators resolved 
should prevent 78 ADR-related hospital admissions throughout 2016. These results, 
therefore, illustrate the huge potential for the STOPP/START toolkit to improve patient 
safety, and so support the use of the STOPP/START toolkit in PMRs. 
 
Research limitations/implications 
 
Limitations 
 
The telephone interview approach to data collection was flawed. Firstly, attempts to contact 
patients were unsuccessful in 31 patient cases, as the number was either unrecognised, or 
patients failed to answer. In addition, over the telephone it was difficult to identify which 
patients were ‘well’ enough to complete the interview. Four of the patients contacted 
displayed obvious signs of confusion, with one explaining that they had recently had a stroke 
and so found remembering difficult. In these cases, interviews could not be completed. As 
with all interviews, there was also the possibility of patient dishonesty, as despite being 
informed otherwise, patients may have believed that their responses would be fed back to 
the doctor. This may have caused enhanced result positivity. 
 
The study was also weak in that the participant sample was not wholly representative of all 
patients in North Kirklees aged 75 years or above who are prescribed ten or more repeat 
medications: the target population. This is because the study excluded all patients 
diagnosed with dementia, amnesia, schizophrenia and/or severe depression. Owing to the 
lack of a language interpreter, all patients with a poor understanding of English were also 
excluded. Arguably, the patients excluded from the study are those most in need of a PMR. 
Results may, therefore, be skewed and may not be applicable to the whole population. 
 
The retrospective nature of the study also emerged as a barrier to attaining reliable results, 
as some patients, when contacted, said they were unable to remember the review well 
enough to answer the questions. This highlights a need for a reduced time frame between 
the carrying out of the medication review and the follow-up interview, should a similar study 
be conducted in the future. 
 
Future research 
 
It would be useful to understand a GP’s perception of the STOPP/START toolkit, as 
ultimately, GPs are using the tool and are responsible for accepting or rejecting alerts. More 
research could, therefore, be conducted focusing solely on clinician opinions on the success 
of the STOPP/START tool in PMRs. It may also be interesting to trial the use of the 
STOPP/START toolkit by other healthcare professionals (HCPs), such as pharmacists, who 
conduct medication reviews (Royal Pharmaceutical Society, 2016). Subsequent research 
into their opinion on the toolkit may also be beneficial. 
 
In addition, as this study was specific to the North Kirklees region, it may be beneficial to 
conduct research on patients located in other areas of the United Kingdom. This would 
improve the generalisability of the findings. 
 
Practical implications 
 
PMRs and the need for STOPP/START 
 
From the results, it is evident that the vast majority of polypharmacy patients aged 75 years 
or over deem PMRs to be useful and, hence, leave feeling satisfied. The results also identify 
that PMRs are an ideal opportunity to increase patient understanding with regard to their 
medication, a factor that has the potential to improve patient adherence. The findings, 
therefore, support continued commissioning of annual medication reviews on polypharmacy 
patients. 
 
Although it would seem that PMRs are useful as a stand-alone entity, the results of the study 
suggest that PMR outcome can be benefited by activation of the STOPP/START toolkit. This 
is because it has been found that patients perceive greater inclusion in decisions regarding 
the stopping and/or starting of medications if these decisions are responsive to a 
STOPP/START alert. Increased decision inclusion enhances patient satisfaction in the 
changes made. Furthermore, as STOPP/START alerts are linked with RCGP prescribing 
safety indicators, resolution of these alerts has significant potential to decrease the risk of 
ADRs. This should, in turn, decrease hospital admissions, thus increasing patient safety and 
decreasing the financial burden on the NHS. Based on these advantages, activation of 
STOPP/START should be continued in future PMRs. 
 
Shared decision-making 
 
A strong association was found in this research project between patient-perceived inclusion 
in decisions and patient satisfaction. This suggests a need for the adoption of a shared 
decision-making approach by clinicians, not only in PMRs, but also in other consultations. 
 
Despite there being a clear need for shared decision-making, it would appear that this is not 
common practice for GPs, as only half of the patients interviewed stated that they feel 
involved in medication change decisions. It may, therefore, be beneficial for HCPs, in 
particular HCPs in primary care, to be offered training regarding this consultation style. 
 
Location and occupation 
 
It was evident from the results that patients valued time to focus solely on their medicines. 
PMRs should, therefore, continue to be of 20 minutes’ duration, despite this being double the 
length of a normal routine consultation. In the current health economy, GPs are, however, 
restricted in their time availability and so such a long duration may be impractical. A potential 
solution to this could be to trial the conduction of STOPP/START-aided PMRs by other 
HCPs, for example, community and hospital pharmacists and nurses, and hospital clinicians. 
 
Social implications 
 
Patient education 
 
Within the study, a large proportion of patients reported improved understanding of both the 
need for and how to take/use their medication post-PMR. As such improvements were 
reported, this firstly highlights a need for improved medication education amongst elderly 
patients, and secondly volunteers PMRs as a successful method for achieving this required 
education. By improving patient understanding regarding medication, PMRs also have the 
potential to decrease unintentional non-adherence, a significant problem associated with 
polypharmacy (NHS England, 2015). 
 
In addition, some patients within the study were unable to answer the question regarding 
perceived PMR usefulness. This may be due to a lack of patient understanding of the 
purpose of a PMR. This subsequently indicates a need for better patient information 
regarding the review and its purpose before PMR conduction, to ensure patients gain full 
benefit from the review. 
 
Patient safety 
 
As was demonstrated by the study’s findings, resolution of STOPP/START triggers 
decreases the risk of ADRs and, consequently, should decrease potentially avoidable ADR-
related hospital admissions. Admission to hospital is associated with infection risk and 
burden on the NHS (Pirmohamed et al., 2004). If STOPP/START-aided PMRs continue to 
be commissioned, as is recommended by this study, there should be both improved patient 
safety and decreased demand on secondary care resources. 
 
Originality/value 
 
This paper has allowed assessment of the opinions of polypharmacy patients aged 75 years 
or over regarding their PMR. Analysis of the RCGP indicator linked STOPP/START triggers 
has also enabled insight into the extent to which the STOPP/START toolkit can potentially 
improve patient safety. 
 
Overall, this paper provides support for both PMRs and the STOPP/START toolkit. It does, 
however, also highlight issues associated with the conduct of PMRs, and attempts to offer 
some solutions to such problems, for example, a training focus on shared decision-making to 
improve PMR outcomes. This paper also encourages further research. 
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